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A B S T R A C T
Conventional anticancer therapies such as radiotherapy and chemotherapies are associated with oxidative stress
generating reactive oxygen species (ROS) and reactive aldehydes like 4-hydroxynonenal in cancer cells that
govern them to die. The main mechanism activated due to exposure of the cell to these reactive species is the
Nrf2-Keap1 pathway. Although Nrf2 was firstly perceived as a tumor suppressor that inhibits tumor initiation
and cancer metastasis, more recent data reveal its role also as a pro-oncogenic factor. Discovery of the
upregulation of Nrf2 in different types of cancer supports such undesirable pathophysiological roles of Nrf2. The
upregulation of Nrf2 leads to activation of cytoprotective genes thus helping malignant cells to withstand high
levels of ROS and to avoid apoptosis, eventually becoming resistant to conventional anticancer therapy.
Therefore, new treatment strategies are needed for eradication of cancer and in this review, we will explore two
opposing approaches for modulation of Nrf2 in cancer treatments.
1. Introduction
Cancer still remains one of the leading causes of death worldwide
with alarming expectancy to rise a further 75% over the next two
decades [1]. Hence, there is a constant need of finding new treatment
strategies and drugs that will combat cancer or at least will improve
survival rate and quality of life of patients. Although many different
types of cancer can be distinguished, each being unique as is the ill
person unique, more generally cancer is described as an uncontrollable
growth of abnormal cells persisting even after the cease of its etiological
cause that can happen in any type of tissue and can spread all over the
body giving rise to metastatic disease. The complexity of cancer was
reviewed by Hanahan &Weinberg in [2], who proposed eight hallmarks
of cancer with two enabling characteristics, which are acquired by
cancer cells during the multistep process of development of human
tumors. These include: sustaining proliferative signaling, evading
growth suppressors, activating invasion and metastasis, enabling repli-
cative immortality, inducing angiogenesis, resisting cell death, dereg-
ulating cellular energetics, avoiding immune destruction, genome
instability and mutation, and tumor-promoting inflammation [2]. The
authors based their explanation of cancer phenotypes on the premises
adopted by the somatic mutation theory, while some critics advocate
the tissue organization field theory, in which cancer is viewed as a
tissue-based disease similar to "development gone awry”, as a better
alternative [3,4]. Though new theories are emerging each day [5–7].
Irrespective of each preference to certain theory, different signaling
pathways affected by diverse growth factors, transcriptional factors and
other signaling molecules such as reactive oxygen species (ROS) or their
consequential end-products (e.g. 4-hydroxynonenal (HNE)) are impor-
tant in cancer development (reviewed in [2,8–11]). In this review
paper, we will focus on the role of nuclear factor erythroid 2 [NF-E2]-
related factor 2 (Nrf2) in carcinogenesis and on two different ap-
proaches arisen in the cancer therapy based on Nrf2 modulation.
2. Nrf2-Keap1 pathway
To defend themselves from stress conditions induced by oxidative
stress and xenobiotics, cells have evolved defense mechanisms that will
keep them alive. The main mechanism activated in such conditions is
Nrf2 – Keap1 (Kelch-like ECH-associated protein 1) pathway.
Nrf2 is a basic leucine zipper (bZip) transcription factor with a Cap
“n” Collar (CNC) structure [12]. In homeostatic conditions, Nrf2 is
bound to its repressor Keap1 and thus subjected to ubiquitin-dependent
degradation in proteasomes. However, in stress conditions, Nrf2
becomes released from Keap1 and translocated into nucleus where it
forms heterodimers with small Maf proteins and binds to antioxidant
response element (ARE) of the target genes guiding their activation and
thus cytoprotection of the cell (Fig. 1) [13]. Target genes activated by
Nrf2 are involved in: 1) synthesis of glutathione (Glutamate-cysteine
ligase, catalytic subunit (Gclc), glutamate-cysteine ligase, modifier
subunit (Gclm)), 2) elimination of ROS (Thioredoxin reductase 1
(Txnrd1), Peroxiredoxin 1 (Prdx1), 3) detoxification of xenobiotics
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(NAD(P)H dehydrogenase, quinone 1 (Nqo1), Glutathione S-transferase
(Gst) gene family) and 4) drug transport (Multidrug resistance-asso-
ciated protein (Mrp) gene family) [13].
3. Role of oxidative stress and Nrf2-Keap1 pathway in
carcinogenesis
For a long time, radical species, such as ROS, emerged during
oxidative stress have been considered as harmful, co-carcinogenic
factors of cancer development. For instance, in infection-associated
cancers such as human papilloma virus-induced cervical cancer,
hepatitis B virus-positive hepatocarcinoma, and Helicobacter pylori-
positive gastric cancer, chronic infection leads to generation of ROS as
the first line of antimicrobial defense, which in turn can initiate cancer
development [14]. ROS comprise mostly of hydrogen peroxide (H2O2),
superoxide anion (O2•-) and hydroxyl radical (•OH). Both, endogenous
(mitochondrial electron transport chain, xanthine oxidase (XO), nico-
tinamide adenine dinucleotide phosphate (NADPH) oxidase (NOX),
peroxisomes and cytochrome P450) and exogenous sources (ultraviolet
light, ionizing radiation, pharmaceuticals, environmental agents, and
industrial chemicals) contribute to their generation [8,15]. ROS are
highly reactive by nature and as such cause oxidation of the cellular
macromolecules (DNA, proteins, lipids) thus contributing to chromo-
some instability, genetic mutation, and/or modulation of cell growth
[8,9,15,16]. It has been postulated that cancer cells have higher levels
of ROS than normal cells. Yet, they can withstand these levels by
activation of certain pathways that drive their proliferation and
survival. These pathways include activation of antioxidant machinery
to reduce ROS, but also reprogramming of metabolic pathways that can
generate additional ROS and make cancer cells more vulnerable to
forthcoming stress. Indeed, recent findings by Harris et al. suggested
that glutathione (GSH) and thioredoxin play important role in carcino-
genesis, with GSH being important in cancer initiation while in already
established cancers thioredoxin is a key player that abolishes detri-
mental levels of ROS and governs cancer progression [17,18].
Therefore, antioxidant defense (endogenous and exogenous) to-
gether with ROS have been known for their dual role in carcinogenesis.
It is noteworthy to mention that ROS are short lived and their oxidation
of lipids is generating longer living molecules known as second
messengers of oxidative stress [19]. One of the most intensively studied
among them is 4-hydroxynonenal (HNE). HNE is a highly reactive
aldehyde, more stable than ROS, which can easily react with cellular
macromolecules such as proteins, DNA and phospholipids. HNE can
also act as signaling molecule affecting cell proliferation, differentia-
tion, and apoptosis and as such has been implicated in different cancers
[20–22]. HNE is a potent inducer of Nrf2 either by covalently binding
to cysteine sites in Keap1 protein and thus disrupting Keap1-dependent
degradation of Nrf2, or by activating Nrf2 through activation of
upstream kinases such as PKC, ERK and PI3K [23–26]. Furthermore,
HNE is metabolized through activation of Nrf2 as well.
The main signaling pathway activated to amend disturbed redox
balance is Nrf2-Keap1 pathway. Current research recognizes dual role
of Nrf2 in carcinogenesis: protective in early stages and detrimental in
later stages (Fig. 2). When present in lower levels that are sufficient to
maintain homeostasis, Nrf2 is eliminating ROS, carcinogens, and other
DNA-damaging agents, which leads to inhibition of tumor initiation and
cancer metastasis. Supporting Nrf2 protective role is evidence that a
single nucleotide polymorphism in the human Nrf2 upstream promoter
region (rs6721961), which may result in reduced Nrf2 gene expression,
is increasing a risk of lung cancer in current and even in former smokers
[27].
In cancer, Nrf2 is usually upregulated, thus helping malignant cells
to withstand high levels of ROS and avoid apoptosis through activation
of metabolic and cytoprotective genes that contribute to enhanced cell
proliferation [12,28–34]. Different mechanisms lead to observed in-
creased Nrf2 activity in cancers, such as: 1) somatic mutations in Nrf2,
Keap1, or Cul3; 2) epigenetic silencing of Keap1; 3) microRNA-
mediated regulation of Nrf2 and Keap1; 4) disruption of Nrf2-Keap1
interaction by aberrantly accumulated proteins; 5) transcriptional up-
regulation of Nrf2 through oncogene-dependent signaling; and 6)
modification of Keap1 by metabolic intermediates [12,29,30]. For
instance, recent data revealed the necessity of Nrf2 in sustaining
proliferation in pancreatic cancer through the regulation of mRNA
translation. The loss of Nrf2 led to defected autocrine signaling of
epidermal growth factor receptor (EGFR) and to oxidation of specific
proteins of translational machinery, which resulted in impaired cap-
dependent and cap-independent mRNA translation [35]. In human
leukemia, Nrf2 was found to be constitutively activated, and in acute
myeloid leukemia (AML), the activation of Nrf2 is a result of upstream
constitutive activation of nuclear factor-κB (NF-κB) and not of somatic
mutation of Nrf2 or its inhibitor Keap1 [36]. Moreover, recent data
showed increased expression of Nrf2 in non-small cell lung cancers,
such as squamous cell carcinoma (SCC) and adenocarcinoma (AC) with
different involvement of oxidative stress-induced lipid mediators
Fig. 1. Schematic overview of the Nrf2 pathway. In homeostatic conditions, transcription factor Nrf2 is bound to its repressor Keap1 and thus subjected to ubiquitin-dependent
degradation in proteasomes. On the other hand, in stress conditions, Nrf2 released from Keap1 is translocated into nucleus where it forms heterodimers with small Maf proteins and
activates cytoprotective genes through antioxidant response element (ARE).
L. Milkovic et al. Redox Biology 12 (2017) 727–732
728
between these two subtypes: more pronounced involvement of lipid
peroxidation in AC and endocannabinoid system in SCC, respectively
[37]. In addition, prostate cancer cell lines have shown different
sensitivity to HNE-mediated inhibition of cell growth and apoptosis.
In particular, DU145 cells exhibited lower levels of Keap1, higher levels
of Nrf2, GSH and GST A4 and greater GSH/GST-mediated HNE
detoxification and thus were less sensitive than PC3 and LNCaP cells
[38]. Furthermore, Nrf2 was recognized as “a key regulator in
chemotherapeutic resistance under hypoxia through ROS-Nrf2-GCLC-
GSH pathway” in breast cancer cells [39]. Therefore, better under-
standing of mediators of oxidative stress with their possible clinical
relevance [40], together with improved knowledge of the role of Nrf2
and its downstream targets could contribute to future, more effective,
anticancer therapy.
While specific role of Nrf2 in cancer still remains controversial,
since Nrf2 is considered as both, a tumor suppressor and a proto-
oncogenic factor, some researchers postulate that its precise role is
dependent on the stage of tumorigenesis [34,41].
4. Cancer therapy and Nrf2
Nowadays drugs affecting redox processes have been recognized as
“a significant expansion of the chemotherapeutic armamentarium”, as
reviewed in [42]. Majority of conventional therapy against cancer
(radiotherapy and many chemotherapeutics) relies on generation of
ROS and consequently HNE, resulting in cancer cell death. Unfortu-
nately, there are limitations in their clinical use because they are
designed to destroy rapidly dividing non-malignant cells, hence, while
not all cancer cells are eliminated, some normal cells are. Besides, these
therapies exert toxicity also well known as undesirable side effects. For
a long time it was considered that antioxidant supplementation during
anticancer therapies could reduce side effects of such therapies, but
recent data suggest more caution is needed due to their observed
unfavorable role when used during cancer therapy [8,43].
Cancer cells are known to adapt to the negative environment by
boosting their pro-survival responses which combined with the de-
crease of therapy-induced ROS by antioxidants, below the critical
threshold required for cell death, may explain observed findings [8].
Perceived resistance of cancer cells to therapy is initiated by a range of
potentially complementary mechanisms, such as the mutation or over-
expression of the drug target, inactivation of the drug, or its elimination
from the cell by ATP-binding cassette (ABC) transporters and RLIP76,
etc. [44–46]. Response mechanisms to the increased redox imbalance
during radio- and/or chemotherapy requires involvement of the Nrf2-
Keap1 pathway, which is the main regulator of cytoprotective responses
to resulting stress. As already mentioned, Nrf2 had been recognized for
its dual role in carcinogenesis; beneficial in the early stages where
activation of the Nrf2 pathway leads to activation of cytoprotective
genes and thus generation of antioxidant machinery that removes ROS,
HNE, and xenobiotics from the cells thus restoring the redox balance
and avoiding unwanted DNA mutations and cancer initiation; but
detrimental in later stages of cancer by increasing resistance to
conventional radio- and/or chemotherapy.
Therefore, open question remains: How does or can antioxidative
defense of cancer cells, activated mainly through Nrf2-Keap1 pathway,
affect anticancer therapy?
4.1. Nrf2 activators
A variety of natural and synthetic compounds have been recognized
as activators of Nrf2 and implicated in prevention of cancer develop-
ment including sulforaphane, curcumin, resveratrol, lycopene, olea-
nane triterpenoid, etc. [29,31,47,48]. Sulforaphane (SFN) is one of the
most intensively studied natural compounds that target the Nrf2–Keap1
signaling. SFN is an isothiocyanate found in cruciferous vegetables such
as broccoli [12]. Several epidemiological studies linked consumption of
broccoli with a lower incidence of cancer including breast, prostate,
lung, stomach and colon cancer [49]. A phase II clinical trial study in
China evaluating the chemo-preventive properties of broccoli sprout
preparations containing>60% glucoraphanin, a precursor of SFN,
determined that SFN reduced afla-toxin–DNA adducts and thus protect
against hepatocellular carcinoma [12,50]. Additionally, in a review
paper by Sharma et al., authors suggest that HNE plays a crucial role in
the mechanisms of the biological activities of SFN which include
selective cytotoxicity to cancer cells by targeting signaling pathways
that provide their specific killing as well as upregulation of defense
mechanisms that protect normal cells against oxidative/electrophilic
stress [51].
Synthetic oleanane triterpenoid, RTA 405 is an antioxidant inflam-
mation modulator (AIM) that displays its antitumor activity by binding
to Keap1 leading to inhibition of Nrf2 degradation, thus increasing Nrf2
activity. Probst et al. compared the influence of RTA 405 on Keap1 with
a constitutive activation of Nrf2 by Keap1 deletion and found these are
indeed different mechanisms that differently affect cancer cell growth
[52]. In particular, cancers with Keap1 loss or mutation usually have
increased levels of Nrf2 and other oncogenic proteins such as IKKβ and
Bcl2, while this was not the case upon RTA 405 treatment where only
levels of Nrf2 were increased but not levels of IKKβ and Bcl2. Moreover,
RTA 405 directly inhibited IKKβ, leading to decreased NF-κB activity,
and consequently, suppression of cancer cell survivor and promotion of
apoptosis. In addition, cancer cells, pretreated with RTA 405, were not
protected from growth inhibition mediated by doxorubicin or cisplatin.
All these finding led to conclusion that genetic activation of Nrf2 and
pharmacological activation of Nrf2 by RTA 405 are distinct and that
RTA 405-mediated activation of Nrf2 does not promote growth or
survival of cancer cells [52].
Fig. 2. Activation of Nrf2 has dual role in carcinogenesis. In carcinogenesis Nrf2 was
recognized to have a dual role: protective in early stages and detrimental in later stages.
Indeed, in early stages, sufficient Nrf2 levels maintain homeostasis by eliminating
carcinogens, such as ROS and other DNA-damaging agents, and thus inhibit tumor
initiation and cancer metastasis. Whereas, in cancer, Nrf2 is usually upregulated leading
to activation of cytoprotective genes and thus helping malignant cells to endure high
levels of ROS and avoid apoptosis.
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Caution with Nrf2 activators was raised in case of diabetic patients.
Notably, Wang et al. have shown that common classes of drugs used for
treatment of diabetes mellitus type 2, saxagliptin and sitagliptin (the
dipeptidyl peptidase-4 (DPP-4) inhibitors) and α-lipoic acid (ALA) (for
treating diabetic neuropathy), known for their antioxidative properties,
induce prolonged activation of Nrf2 and although they do not enhance
cancer incidence they do increase the risk of metastasis development in
diabetic patients who already have cancer [53].
4.2. Nrf2 inhibitors
Since the oncogenic activity of Nrf2 has also been revealed,
concerns about usage of Nrf2 activators was been raised, too.
Namely, Wang et al. have evaluated expression profile of Nqo1, which
is an Nrf2-downstream target gene, in tissue samples of lung cancer
patients. The tissue samples were ranged from normal to more
advanced cancer stages (stages I, II and III). The elevated expression
of Nqo1 was present in patients with stage II and stage III lung cancer.
Moreover, they were interested in what role does Nrf2 have in response
to drug treatments in different cancers (lung carcinoma, breast adeno-
carcinoma and neuroblastoma). They found that upregulation of Nrf2
increases resistance of cancer cells while downregulation of Nrf2 makes
cancer cells more sensitive to chemotherapeutic drugs such as cisplatin,
doxorubicin and etoposide. Therefore, to increase the efficacy of
anticancer drugs in cancer patients, they suggested the usage of Nrf2
inhibitors that will inhibit the Nrf2-dependent response [54]. Hence,
current research is trying to find Nrf2 inhibitors and elucidate their role
in cancer therapy. We will list just some of them.
Malabaricone-A (MAL-A) is a pro-oxidant compound suggested to
likely be more effective in leukemia than solid tumors and its mode of
action is directed on targeting Nrf2 antioxidant pathway, by decreasing
levels of Nrf2 and increasing redox imbalance [55]. Moreover, MAL-A
induces peroxidation of cardiolipin [55], a source of HNE [56]. Since
HNE is known as a second messenger of oxidative stress and in high
concentrations it governs cancer cell to apoptosis, we can postulate that
HNE together with the decrease of Nrf2 may have been employed in
this increased chemosensitivity. In favor of this assumption are the most
recent data from in vitro and clinical study that revealed a gradual
decrease of cardiolipin in tissue samples of hepatocellular carcinoma in
comparison to non-cancerous tissue leading to decreased oxidation of
cardiolipin and consequently lesser formation of HNE which might be a
possible adaptation mechanism of the cancer cells to avoid apoptosis
[57].
Another mechanism adopted by the cancer cells in hepatocellular
carcinoma that helps them to resist to chemotherapeutic agents is
linked to overexpression of Nrf2 and its downstream targets (multidrug
resistance-associated protein 5 and AKR1B10 – a member of aldo-keto
reductase superfamily) in comparison to adjacent non-cancerous tissue
[58]. Therefore, Gao et al. conducted concomitant in vitro and in vivo
study to explore inhibitory potential of apigenin (a natural bioflavonoid
found in many fruits and vegetables) to Nrf2 pathway. In particular,
apigenin inhibited Nrf2 pathway, observed as decrease of Nrf2 at both
transcriptional and translational levels, which occurred via down-
regulation of PI3K/Akt pathway. Moreover, apigenin sensitized doxor-
ubicin-resistant hepatocellular carcinoma BEL-7402/ADM cells to dox-
orubicin, and in BEL-7402 xenografts, cotreatment of apigenin and
doxorubicin was more effective that doxorubicin treatment alone
observed as inhibition in tumor size [58].
All trans-retinoic acid (ATRA) is another proposed specific Nrf2
inhibitor in which presence Nrf2 is forming a complex with retinoic
acid receptor alpha (RARα). These complexes do not bind to ARE
sequences and the activation of the pathway is blocked [29,47]. Indeed,
retinoic acid has been identified as an inhibitor of Nrf2 in human breast
cancer (MCF-7) cells transfected with an ARE-luciferase reporter
construct [59].
A simplified scheme of the role of Nrf2 activators and inhibitors is
presented in Fig. 3, although we have to highlight that the specific
effect is a compound-used directed since different compounds affect
also other pathways. It is well known that cancer cells are not uniform
and reprogramming of cancer cells contributing to progression of the
disease further impact their heterogeneity. Therefore, the usage of
specific Nrf2 activators or inhibitors during the cancer therapy was
shown to be highly associated with cancer stage.
Noteworthy, Leinonen et al. introduced an alternative approach,
known as suicide gene therapy, using thymidine kinase (TK) containing
Nrf2-driven vectors (ARE-HSV-TK) for targeting cancer cells with high
constitutive Nrf2 expression. They evaluated this approach in human
lung adenocarcinoma cells and found it effective in both in vitro and in
Fig. 3. Simplified schematic overview of interaction of Nrf2 activators and inhibitors in anticancer therapy. Majority of conventional therapy against cancer relies on generation of ROS
resulting in cancer cell death. Yet, not all cancer cells are affected and they tend to become resistant. Although, diverse mechanisms contribute to perceived resistance, this therapy-
induced increase of redox imbalance requires involvement of the Nrf2-Keap1 pathway which is the main regulator of cytoprotective responses. Observation that a single nucleotide
polymorphism in the human Nrf2, leading to reduced Nrf2 gene expression, increases risk of lung cancer supported Nrf2 protective role. In addition, due to the fact that Nrf2 inhibits
tumor initiation and cancer metastasis by eliminating carcinogens, ROS and other DNA-damaging agents, a variety of its natural and synthetic activators have been implicated in
prevention of cancer development (e.g. sulforaphane, oleanane triterpenoid RTA 405, etc.). Some of them have also shown their beneficial role during cancer therapy by affecting other
mechanism. Examples are: RTA405 which was found to decrease NF-κB activity and thus suppress cancer cell survival and promote apoptosis and sulforaphane (SFN) which selective
cytotoxicity of cancer cells involves generation of HNE (A). Yet, caution in using Nrf2 activators was suggested since they have been implicated in enhanced cancer cell resistance. Due to
the fact that in many cancers, especially in later stages of the disease, Nrf2 and Keap1 are mutated leading to Nrf2 increased activity, inhibitors of Nrf2 were suggested to be a promising
tool that will sensitize cancer cells and increase efficacy of conventional therapy (B). Though, both, Nrf2 activators and inhibitors have shown to be beneficial, e.g. activators mainly in
prevention of cancer incidence and inhibitors during progression of the disease, there is a lot of uncertainties that is pushing us to unveil all the modalities by which Nrf2 can be used as a
therapeutic target.
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vivo, offering an additional promising treatment that could be used in
conjunction with traditional therapies [30,60].
5. Conclusion
Although much effort has been invested, cancer still remains a
puzzle. Current research is trying to elucidate why we are still losing in
our fight against cancer. While conventional therapy has its benefits it
also has its limitations observed as cancer ability to resist to it.
Therefore, researchers intensively work on trying to find mechanisms
involved in cancer adaptation and resistance. The Nrf2-Keap1 pathway
was found to be one of the key mechanisms in these processes.
Therefore, its role is being highly investigated. Though Nrf2 was firstly
perceived as a tumor suppressor, nowadays, it is also recognized as a
proto-oncogene. Hence, along with the research of Nrf2 activators that
inhibit cancer development, an increasing field of research is pursuing
to find inhibitors of Nrf2 that will combat cancer resistance to
conventional therapy.
Thus, a continuous need for better understanding of the modalities
by which Nrf2 can be used as a therapeutic target, still remains to be
carried complementary with the research of clinical relevance and
involvement of mediators of oxidative stress especially of HNE, in
cancer and in the anticancer therapy.
Dedication
This review is dedicated to those who suffer from cancer and to
those who try to help them.
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